DBS Bank downgraded Novo Nordisk (NVO) to Sell from Buy with a DKK 330 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk downgraded to Market Perform from Outperform at BMO Capital
- ‘Time to Make a Warren Buffett Move,’ Says Top Investor About Novo Nordisk Stock
- Eli Lilly Stock (LLY) Back in Shape as It Sues Compounders Over Weight-Loss Drugs
- Hims & Hers Stock (HIMS) Dips After FDA Flags Safety Concerns
- Clinical Trial Success Positions Eli Lilly Stock (LLY) for Major Rebound